A ranar 1 ga Mayu, 2025, Hansoh Pharmaceutical ta sanar da cewa maganin rigakafi na B7-H4 da aka haɓaka da kansa (ADC) HS-20089 na ƙungiyar don allura ya sami amincewar a haɗa shi a matsayin maganin da Hukumar Kayayyakin Lafiya ta Ƙasa (NMPA) ta China ta tsara, tare da shawarar da aka bayar ga marasa lafiya da ke fama da cutar kansa ta ovarian mai jure wa platinum, ciwon daji na bututun fallopian ko ciwon daji na farko na peritoneal.
An tallafawa wannan sunan ne ta hanyar sakamakon binciken Phase I HS-20089-101 da kuma binciken Phase II HS-20089-201. Binciken HS-20089-101 gwaji ne na Phase I mai cibiya da yawa, mai lakabin budewa don kimanta aminci, juriya, pharmacokinetics, da ingancin HS-20089 don allura ga marasa lafiya da ke da ciwace-ciwacen da suka yi tsanani. Binciken HS-20089-201 gwaji ne na Phase II mai cibiya da yawa, mai lakabin budewa don tantance inganci, aminci, bayanin pharmacokinetic, da kuma juriyar HS-20089 a cikin jijiya ga marasa lafiya da ke fama da cutar kansar ovarian da kuma ciwon daji na endometrial.
HS-20089 wani nau'in ADC ne da aka yi niyya ga B7-H4 tare da topoisomerase inhibitor (TOPOi) wanda ake haɓaka don magance cutar kansar mahaifa da sauran ciwace-ciwacen mata a gwaje-gwajen asibiti da yawa a China, inda matakin bincike mafi girma shine gwaje-gwajen asibiti na Mataki na III. B7-H4 wani glycoprotein ne mai kariya daga garkuwar jiki wanda ke bayyana sosai a cikin ciwace-ciwacen da yawa, gami da ciwon endometrial da ciwon daji na ovarian, amma tare da ƙarancin bayyanar a cikin kyallen takarda na yau da kullun.
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Imel:myimmnet@163.com
Lokacin Saƙo: Mayu-09-2025